Management of Hydatidiform Mole
The recommended management for hydatidiform mole is immediate suction curettage under anesthesia, followed by serial serum hCG monitoring every 2 weeks until normalization, then monthly for 6 months after complete mole (or one additional normal value for partial mole). 1
Initial Diagnostic Workup
Before proceeding to evacuation, obtain:
- Pelvic ultrasound (uterine artery Doppler is optional)
- Serum hCG level (baseline for monitoring)
- Chest X-ray if clinical suspicion of metastases or as baseline
- Blood group and crossmatch (significant hemorrhage risk)
- Thyroid function tests if hyperthyroidism suspected (hCG can stimulate thyroid)
Surgical Management
Primary Treatment: Suction Curettage
Suction curettage under anesthesia is the treatment of choice due to high efficacy and safety profile 1, 2. This procedure should be performed with:
- US-guided technique to ensure complete evacuation and avoid perforation 1
- Blood products immediately available pre-operatively (these procedures can cause significant blood loss) 1
- Anti-D immunization for Rh-negative women 1
- Oxytocin administration (consider for uterine contraction) 1
Cervical ripening can be considered before the procedure, though there is no strong evidence either for or against this practice 1.
Adjunctive techniques such as hysteroscopy and intraoperative ultrasonography enhance safety and effectiveness, particularly at specialized referral centers 2.
Alternative: Hysterectomy
In selected cases, hysterectomy is an appropriate option, specifically for:
- Older women without desire for future fertility
- Women at high risk of developing post-molar gestational trophoblastic neoplasia (GTN)
This approach reduces (but does not eliminate) the risk of post-molar GTN.
Pathologic Confirmation
Send all tissue for histologic examination to differentiate between:
- Complete hydatidiform mole (CHM)
- Partial hydatidiform mole (PHM)
- Hydropic miscarriage (non-molar)
Reference pathology review by an experienced pathologist or GTD center within 2 weeks is best practice, as differentiation can be difficult. Ancillary techniques including genetic analysis may be helpful 1.
Post-Evacuation Monitoring Protocol
hCG Surveillance
Monitor serum hCG at least once every 2 weeks until normalization, preferably using an hCG assay advised by the GTD center 1.
After normalization:
- Partial mole (PHM): Obtain one additional normal hCG value over 1 month, then discharge 1
- Complete mole (CHM): Continue monthly hCG monitoring for up to 6 months (though recurrence risk is very small after normalization) 1
This monitoring strategy is supported by evidence showing that no patient who spontaneously achieved normal hCG levels subsequently developed persistent molar disease 3, 4. For patients achieving normal hCG within 2 months of evacuation, it appears safe to discontinue monitoring once normal levels are achieved 3.
Criteria for GTN Diagnosis
Gestational trophoblastic neoplasia (GTN) is diagnosed if:
- hCG plateaus over 3 consecutive values one week apart, OR
- hCG rises over 2 consecutive values one week apart
These are the FIGO criteria for post-molar GTN.
Risk Stratification
Understanding malignant potential guides counseling:
- Complete moles: 15-20% develop post-molar GTN 5
- Partial moles: Only 1-5% develop post-molar GTN 5
- Overall GTN rate after molar pregnancy: 18-29% 5
Higher risk features include:
- Bilateral ovarian enlargement
- Large-for-dates uterus
Critical Pitfalls to Avoid
- Do not skip hCG monitoring - This is essential for detecting the 15-20% of complete moles that progress to GTN
- Do not allow pregnancy during monitoring period - Reliable contraception is mandatory until hCG monitoring is complete
- Do not perform medical evacuation - Suction curettage is preferred over medical management
- Do not delay blood product availability - Have crossmatched blood ready before the procedure
Registration and Follow-up
Discuss and/or register all cases with a GTD center after pathologic confirmation 1. This ensures appropriate monitoring protocols and access to specialized care if GTN develops.
The cure rate for appropriately managed hydatidiform mole approaches 100%, with fertility preservation typically maintained 5.